Clinical Trials - BLRX

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT05293171Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy SubjectsCOMPLETEDPHASE12021-06-112022-08-152022-06-01
NCT03246529A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)ACTIVE_NOT_RECRUITINGPHASE32018-03-232029-09-302020-12-22
NCT03154827Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)TERMINATEDPHASE1, PHASE22018-01-082020-04-012020-04-01
NCT02826486Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer PatientsCOMPLETEDPHASE22016-092022-09-062022-09-06
NCT02462252Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic SyndromeCOMPLETEDPHASE22015-102020-112020-11
NCT02073019A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy VolunteersCOMPLETEDPHASE12014-082015-072015-07
NCT01990885Safety and Systemic Exposure Study of BL-7010 in Well-Controlled Celiac Patients.COMPLETEDPHASE1, PHASE22013-122014-102014-10
NCT01838395Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML PatientsCOMPLETEDPHASE22013-042023-07-202016-03
NCT01833845Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis CTERMINATEDPHASE1, PHASE22013-042014-042014-04
NCT01506362Efficacy, Pharmacodynamics, Safety and Tolerability of Oral BL-7040 in Patients With Moderately Active Ulcerative ColitisCOMPLETEDPHASE22012-032013-052013-05
NCT01121380A Study Intended to Evaluate Safety, Tolerability and Pharmacokinetics (PK) Parameters of BL-1021TERMINATEDPHASE12011-062011-102011-10
NCT01363349Phase IIb-III Study of BL-1020 Small Molecule for SchizophreniaTERMINATEDPHASE2, PHASE32011-052013-042013-03
NCT00567710A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II StudyCOMPLETEDPHASE22008-072009-092009-07
NCT00722176Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020COMPLETEDPHASE22008-062009-122009-07
NCT00557531Safety and Feasibility of the Injectable BL-1040 ImplantUNKNOWNPHASE1, PHASE22008-032014-012010-01
NCT00480571Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective DisorderCOMPLETEDPHASE22007-062007-122007-12
NCT00480246A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET TracerCOMPLETEDPHASE12007-05
NCT00374881A Study of the Safety and Efficacy of Combination Therapy With Morphine, Phenylephrine and Sorbitol in Human SubjectsCOMPLETEDPHASE1, PHASE22006-092007-082007-06